Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9020731 | 0.83 | HTR2C (0.52) | HTR2CSCN2AHRH1HRH4KDM1A | |
| SCHEMBL5120222 | 0.81 | HTR2C (0.38) | HTR2CKDM1A | |
| SCHEMBL4790156 | 0.80 | NISCH (0.37) | HTR2CHTR1AHTR7PARP10PARP11 | |
| SCHEMBL4790258 | 0.78 | NISCH (0.46) | HTR2CPARP10PARP11IDO1 | |
| SCHEMBL7435086 | 0.78 | HTR2C (0.49) | HTR2CSCN2AHRH1HRH4 | |
| SCHEMBL4789903 | 0.77 | ADRA2A (0.41) | HTR2CHRH1HRH4IDO1IKBKB | |
| SCHEMBL4790265 | 0.77 | HTR2C (0.54) | HTR2CSCN2AHRH1PARP10PARP11 | |
| SCHEMBL9767635 | 0.77 | HTR2C (0.43) | HTR2CSCN2AKDM1A | |
| SCHEMBL8543167 | 0.76 | HTR2C (0.44) | HTR2CSCN2AHRH1HRH4KDM1A | |
| SCHEMBL9530357 | 0.76 | HTR2C (0.47) | HTR2CSCN2AHRH1HRH4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | HTR2C 222/4885SCN2A 2974/4885HRH1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.